Therapeutic Vaccine Shows Preliminary Safety, Effectiveness for HPV16+ Cervical Precancerous Condition
THURSDAY, Jan. 30, 2025 -- For patients with human papillomavirus (HPV) type 16 (HPV16)-positive cervical intraepithelial neoplasia grade 3 (CIN3), vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness, according to a study published online Jan. 24 in Clinical Cancer Research.
Anneke L. Eerkens, from the University of Groningen in the Netherlands, and colleagues examined the clinical efficacy of Vvax001 in patients with HPV16-positive CIN3. Participants received three immunizations of Vvax001 at a three-week interval and were monitored for regression of CIN3 for up to 19 weeks after the last immunization.
Eighteen patients were enrolled and fully immunized. The researchers found a reduction in CIN3 lesion sizes in 17 of 18 patients (94 percent), which was evident from three weeks onward after the last immunization. Nine of the patients (50 percent) had a histopathological complete response (regression to CIN1 or no dysplasia) and 63 percent of patients had HPV16 clearance. There was no clearance of other HPV types induced by Vvax001. No recurrences have been observed to date, with median and longest disease-free survival of 20 and 30 months, respectively. There were no serious adverse events reported.
"Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 infection in newly diagnosed untreated patients," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Circulating Tumor HPV DNA Can ID HPV+OPSCC Years Before Diagnosis
MONDAY, Sept. 22, 2025 -- Circulating tumor human papillomavirus DNA (ctHPVDNA) can be detected in the blood years prior to HPV-associated oropharyngeal squamous cell carcinoma...
Nonadherence to Cervical Cancer Screening Increased After COVID-19 Pandemic
THURSDAY, Sept. 18, 2025 -- Nonadherence to cervical cancer screening in the United States increased after the COVID-19 pandemic, according to a study published online Sept. 10...
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.